Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Alkahest, Inc.

Thorsten Pachur

Waldemar F Pfrengle

Adil Duran

Thomas Nicola

Marco Santagostino

Markus Frank

Uwe Stertz

Ulrike Werthmann

Manuel Henry

Thomas Trebing

Hans Haeberle

Matthias Eckhardt

Georg Dahmann

Holger Wagner

Juergen Schnaubelt

Günther Huchler

The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.

Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines

This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Co-crystals and salts of CCR3-inhibitors

The present invention relates to compounds of formula I wherein Rdenotes F or CF, Rdenotes H or C-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.

Process and intermediates for preparing GPR40 agonists

The invention relates to enantiomerically pure 3-(phthalimido)piperidines and processes for preparing enantiomerically pure 3-(phthalimido)piperidines.

Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines

The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines. The process involves reacting a compound of the formula (III) with 3-(phthalimido)piperidine or an enantiomer thereof where X is a leaving group selected from halogens and sulphonic ester acid residues, and Rto Rare as defined herein, to obtain a compound of the formula (II) and deprotecting the obtained compound of the formula (II) to obtain the product xanthines.

Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines

Growing community of inventors

Biberach an der Riss, Germany

Thorsten Pachur